• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AZACITIDINE Drug Record

  • Summary
  • Interactions
  • Claims
  • AZACITIDINE chembl:CHEMBL1489 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    NSC-102816
    VIDAZA
    AZACITIDINE
    LADAKAMYCIN
    U-18496
    AZACITIDINUM
    5-AZAC
    AZACYTIDINE
    4-AMINO-1-BETA-D-RIBOFURANOSYL-S-TRIAZIN-2(1H)-ONE
    AZACITIDINA
    5-AZACYTIDINE
    VIDAZA®
    5 AZC
    pubchem.substance:46509032
    rxcui:1251
    drugbank:00928
    chemidplus:320-67-2
    pubchem.compound:9444
    chembl:CHEMBL1489

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Drug Class antineoplastic agents
    Year of Approval 2004
    Drug Categories drugs that are mainly renally excreted
    Drug Categories nucleic acid synthesis inhibitors
    Drug Categories nucleoside metabolic inhibitor
    (8 More Sources)

    Publications:

    Baiocchi et al., 2003, 5-azacytidine reactivates the erythroid differentiation potential of the myeloid-restricted murine cell line 32D Ro., Exp. Cell Res.
    Fenaux, 2005, Inhibitors of DNA methylation: beyond myelodysplastic syndromes., Nat Clin Pract Oncol
    Kaminskas et al., 2005, FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension., Oncologist
    Ghoshal et al., 2007, DNA methyltransferases as targets for cancer therapy., Drugs Today
    Leone et al., 2003, Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS., Clin. Immunol.
    Silverman et al., 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B., J. Clin. Oncol.
    Hollenbach et al., 2010, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines., PLoS ONE
    Silverman, 2001, Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS)., Oncologist
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Glover et al., 1987, Biochemistry of azacitidine: a review., Cancer Treat Rep
    O'Dwyer et al., 2008, Azacitidine and the beginnings of therapeutic epigenetic modulation., Expert Opin Pharmacother
    Cataldo et al., 2009, Azacitidine for the treatment of myelodysplastic syndrome., Expert Rev Anticancer Ther
    Creusot et al., 1982, Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine., J. Biol. Chem.
    Lin et al., 2001, GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells., Am. J. Pathol.
    Bejar et al., 2014, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients., Blood
    Itzykson et al., 2011, Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias., Leukemia
    López-Karpovitch et al., 2002, Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia., Cytokine
    Kato et al., 2003, Expression of pericyte, mesangium and muscle markers in malignant rhabdoid tumor cell lines: differentiation-induction using 5-azacytidine., Cancer Sci.
    Avvedimento et al., 1989, Reactivation of thyroglobulin gene expression in transformed thyroid cells by 5-azacytidine., Cell
    el Yaagoubi et al., 1998, 5-Azacytidine modulates gamma-glutamyltransferase and glutathione levels in two human prostatic adenocarcinoma cell lines., Biochem. Mol. Biol. Int.
    von Wronski et al., 1994, Effect of 5-azacytidine on expression of the human DNA repair enzyme O6-methylguanine-DNA methyltransferase., Carcinogenesis
    Januchowski et al., 2005, Effect of 5-azacytidine and procainamide on CD3-zeta chain expression in Jurkat T cells., Biomed. Pharmacother.
    Ravandi et al., 2013, Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation., Blood
    Strati et al., 2015, Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome., Am. J. Hematol.
    Hsiao et al., 1996, Comparison of transformation by manganese sulfate and 5-azacytidine in Rat 6 cells overexpressing the c-myc oncogene., Carcinogenesis
    Visani G et al., 2018, MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine., Pharmacogenomics J
    John et al., 1989, Extensive changes in DNA methylation patterns accompany activation of a silent T-DNA ipt gene in Agrobacterium tumefaciens-transformed plant cells., Mol. Cell. Biol.
    Xing et al., 1999, Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation., Int. J. Cancer
    Borodovsky et al., 2013, 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft., Oncotarget
    Cook et al., 1983, Effect of 5-azacytidine on rat liver alpha-fetoprotein gene expression., Biochem. Biophys. Res. Commun.
    Fanciullino R et al., 2015, Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome., Pharmacogenet Genomics
    del Senno et al., 1986, Methylation and expression of c-myc and c-abl oncogenes in human leukemic K562 cells before and after treatment with 5-azacytidine., Cancer Detect. Prev.
  • AZACITIDINE   TRIT1

    Interaction Score: 3.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2479825


    Sources:
    NCI

  • AZACITIDINE   ASXL1

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    25224413


    Sources:
    JAX-CKB

  • AZACITIDINE   TAGLN

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14662021


    Sources:
    NCI

  • AZACITIDINE   TET2

    Interaction Score: 1.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Clinical Study
    Response Type sensitive
    Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm

    PMIDs:
    25224413 21494260


    Sources:
    JAX-CKB

  • AZACITIDINE   CD247

    Interaction Score: 1.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15795105


    Sources:
    NCI

  • AZACITIDINE   DNMT1

    Interaction Score: 0.97

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name azacitidine,Vidaza
    Novel drug target Established target
    Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor

    PMIDs:
    16341239 15793220 17612710 14585280 12011120 20126405 11700387 11752352 2443243 18627335 19589026 6173384


    Sources:
    DrugBank TdgClinicalTrial ChemblInteractions NCI TEND TTD

  • AZACITIDINE   GATA2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12706120


    Sources:
    NCI

  • AZACITIDINE   CDA

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25850965


    Sources:
    PharmGKB

  • AZACITIDINE   IL11

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12543079


    Sources:
    NCI

  • AZACITIDINE   LIF

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12543079


    Sources:
    NCI

  • AZACITIDINE   DNMT3A

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction DNA (cytosine-5)-methyltransferase 3A inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AZACITIDINE   AFP

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6197072


    Sources:
    NCI

  • AZACITIDINE   TG

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2476239


    Sources:
    NCI

  • AZACITIDINE   GGT1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9801800


    Sources:
    NCI

  • AZACITIDINE   MGMT

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7511991


    Sources:
    NCI

  • AZACITIDINE   MYC

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9006118


    Sources:
    NCI

  • AZACITIDINE   TYMS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29205204


    Sources:
    PharmGKB

  • AZACITIDINE   PLAU

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10209960


    Sources:
    NCI

  • AZACITIDINE   FLT3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy Azacitidine + Midostaurin
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive

    PMIDs:
    23613521 25530214


    Sources:
    JAX-CKB MyCancerGenomeClinicalTrial

  • AZACITIDINE   GSTP1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11696442


    Sources:
    NCI

  • AZACITIDINE   ABL1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2425967


    Sources:
    NCI

  • AZACITIDINE   HBB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   THPO

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   RORC

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   IDH1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type grade III astrocytoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24077805


    Sources:
    DTC JAX-CKB

  • AZACITIDINE   NR3C1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   HTT

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   SMAD3

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   ATAD5

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   TP53

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   ALDH1A1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   GMNN

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AZACITIDINE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB00928

    • Version: 5.1.7

    Alternate Names:
    AZACITIDINE DrugBank Drug Name
    320-67-2 CAS Number
    Azacitidine Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Kaminskas et al., 2005, FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension., Oncologist
    Hollenbach et al., 2010, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines., PLoS ONE
    Glover et al., 1987, Biochemistry of azacitidine: a review., Cancer Treat Rep

  • TEND: AZACITIDINE

    • Version: 01-August-2011

    Alternate Names:
    AZACITIDINE Primary Drug Name

    Drug Info:
    Year of Approval 2004
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: AZACITIDINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: AZACYTIDINE

    • Version: 14-September-2017

    Alternate Names:
    C288 NCI drug code

    Drug Info:

    Publications:
    López-Karpovitch et al., 2002, Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia., Cytokine
    Xing et al., 1999, Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation., Int. J. Cancer

  • NCI: 5-AZACYTIDINE

    • Version: 14-September-2017

    Alternate Names:
    C288 NCI drug code

    Drug Info:

    Publications:
    Avvedimento et al., 1989, Reactivation of thyroglobulin gene expression in transformed thyroid cells by 5-azacytidine., Cell
    del Senno et al., 1986, Methylation and expression of c-myc and c-abl oncogenes in human leukemic K562 cells before and after treatment with 5-azacytidine., Cancer Detect. Prev.
    Creusot et al., 1982, Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine., J. Biol. Chem.

  • PharmGKB: azacitidine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Visani G et al., 2018, MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine., Pharmacogenomics J
    Fanciullino R et al., 2015, Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome., Pharmacogenet Genomics

  • JAX-CKB: Azacitidine

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Strati et al., 2015, Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome., Am. J. Hematol.
    Ravandi et al., 2013, Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation., Blood
    Borodovsky et al., 2013, 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft., Oncotarget

  • TTD: Azacitidine

    • Version: 2020.06.01

    Alternate Names:
    D09FAZ TTD Drug ID

    Drug Info:

    Publications:

  • DTC: AZACITIDINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1489 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1489

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: AZACITIDINE

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1489

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21